Viral Genetics To Research Experimental HIV/AIDS Treatment

Armen Hareyan's picture

Azusa, Calif.-based ViralGenetics has agreed to partner with the Universityof Colorado-Colorado Springs to conduct research into anexperimental HIV/AIDS treatment, the ColoradoSprings Gazette reports. According to the agreement,Karen Newell, an associate biology professor at the university, willwork over the next year to explain how the Viral Genetics-developedcompound VGV-1 is effective in treating some people living with thedisease.


VGV-1, which uses thymus nuclear protein in asuspension, appears to work by strengthening the body's immune systemto enable it to fight HIV more efficiently, according to thecompany's Web site. Studies have shown it reduced HIV viral loads insome people. Newell's technology involves modulating the immunesystem and stimulating the body's process of attacking harmful cells.The company will provide $25,000 per quarter to UCCS to complete theresearch.

If the research is successful, Viral Genetics couldreceive FDA approvalto use the compound in clinical trials in the U.S. The company saidit plans to spend up to $600,000 to complete independent tests toconfirm Newell's conclusions, the Gazette reports.Trials already have been conducted in Bulgaria, China, Mexico andSouth Africa. When Newell completes her research, Viral Genetics willacquire the rights to the research under the agreement.

Newell's"basic scientific research and discoveries appear to compliment(sic) the over 10 years of human clinical experience we have,"Haig Keledjian, Viral Genetics co-founder and president, said in arelease, adding, "The acquisition of these rights holdssignificant promise to finally" determine exactly how and whythe compound works. "We not only want to show how and why thecompound works, but also improve the product so that it works on allof the patients rather than just some of them," Newell said(Heilman, Colorado Springs Gazette, 1/7).

Reprinted with permission can view the entire KaiserDaily HIV/AIDS Report, search the archives, and signup for email delivery at The Kaiser Daily HIV/AIDS Report is publishedfor, a free service of The Henry J. Kaiser FamilyFoundation.